

Draxis Pharma LLC
Notes to the Financial Statements

As at 31st Mar	2015 USD	2015 INR (' In Thousands)	2014 USD	2014 INR (' In Thousands)
2. SHARE CAPITAL				
Authorized				
Equity Share Capital (1,000 units of no par value)	-	-	-	-
	-	-	-	-
Issued, Subscribed and Paid up				
Equity Share Capital 1,000 units of no par value (Previous Year 1,000 units)	250,100	11,639	250,100	11,639
	-	-	-	-
	250,100	11,639	250,100	11,639
3. RESERVES AND SURPLUS				
Foreign Currency Translation Reserve				
Foreign Currency Translation Reserve Opening	-	3,342	-	-
Foreign Currency Translation Reserve During the Year	-	646	-	3,342
	-	3,988	-	3,342
Surplus as per Statement of Profit and Loss				
As per last Balance Sheet	(495)	(28)	(352)	(19)
Add: Net Profit after tax transferred from Statement of Profit and Loss	(751)	(47)	(143)	(9)
Amount available for appropriation	(1,246)	(74)	(495)	(28)
Total reserve and surplus	(1,246)	3,914	(495)	3,314
4. NON CURRENT INVESTMENTS (At Cost)				
Trade Investments				
Investment in Equity Instruments (Fully Paid up Equity Shares)				
Investment in Subsidiary Companies :				
- Jubilant HollisterStier General Partnership(99.99% Stake)	2,262	141	2,345	141
Add / (less): Share of Profit / (loss) from Partnership Firm	(691)	(43)	(83)	(5)
	1,571	98	2,262	136
5. CASH AND BANK BALANCES				
Cash and cash equivalents				
Balances with banks:				
- On current accounts	283	18	343	21
	283	18	343	21
6. SHORT TERM LOANS AND ADVANCES <i>(Unsecured and considered good)</i>				
- Loans to related parties	247,000	15,438	247,000	14,798
	247,000	15,438	247,000	14,798
Draxis Pharma LLC Notes to the Financial Statements				
For the year ended 31st March,	2015	2015	2014	2014
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
7. OTHER EXPENSE				
Bank Charges	60	4	60	4
Share of loss from partnership firm	691	43	83	5
	751	47	143	9

Draxis Pharma LLC
Balance Sheet

As at 31st Mar	Notes No	2015 USD	2015 INR (' In Thousands)	2014 USD	2014 INR (' In Thousands)
I. EQUITY AND LIABILITIES					
Shareholders' Funds					
Share capital	2	250,100	11,639	250,100	11,639
Reserves & surplus	3	(1,246)	3,914	(495)	3,314
		248,854	15,553	249,605	14,954
	Total	248,854	15,553	249,605	14,954
II. ASSETS					
Non-current assets					
Fixed assets					
Non-current investments	4	1,571	98	2,262	136
		1,571	98	2,262	136
Current assets					
Cash & bank balances	5	283	18	343	21
Short-term loans and advances	6	247,000	15,438	247,000	14,798
		247,283	15,455	247,343	14,818
	Total	248,854	15,553	249,605	14,954

Prakash C Bisht
CFO (Ingredients) & Sr. VP (Group Accounts)
Place : Noida
Date: 07 May, 2015

Draxis Pharma LLC
Statement of Profit and Loss

For the year ended 31st March,	Notes No	2015	2015	2014	2014
		USD	INR (' In Thousands)	USD	INR (' In Thousands)
REVENUE					
Revenue from operations		-	-	-	-
Total revenue		-	-	-	-
EXPENSES					
Other expenses	7	751	47	143	9
Total expenses		751	47	143	9
Profit before tax		(751)	(47)	(143)	(9)
Tax expenses:					
- Current tax		-	-	-	-
- Deferred tax charge/(credit)		-	-	-	-
Profit for the Year		(751)	(47)	(143)	(9)

Prakash C Bisht
CFO (Ingredients) & Sr. VP (Group Accounts)
Place : Noida
Date: 07 May, 2015

Draxis Pharma LLC

Cash flow Statement for the Year Ended

Particulars	31-Mar-15		31-Mar-14	
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
Cash flows from operating activities				
Net Profit/(Loss) before tax	(751)	(47)	(143)	(9)
<i>Adjustments to reconcile net income to net cash provided by operating activities</i>				
Share of loss from partnership firm	691	43	83	5
	691	43	83	5
Net cash inflow/(outflow) in course of operating activities	(60)	(4)	(60)	(4)
B. Cash flow arising from investing activities :				
Net cash inflow/(outflow) in course of investing activities	-	-	-	-
C. Cash flow arising from financing activities :				
Net cash inflow/(outflow) in course of financing activities	-	-	-	-
D. Foreign currency translation difference		1		3
Net Increase in cash & cash equivalents (A+B+C)	(60)	(3)	(60)	(1)
Add: cash & cash equivalents at the beginning of year	343	21	403	22
Cash & cash equivalents at the close of the year	283	18	343	21

Notes:

- 1) Cash Flow Statement has been prepared under the indirect method as set out in the Accounting Standard 3 (AS-3)-" Cash Flow Statements".
- 2) Amounts in brackets are for cash outflows

Prakash C Bisht

CFO (Ingredients) & Sr. VP (Group Accounts)

Place : Noida

Date: 07 May, 2015